Diabetes and endothelial dysfunction: What's the culprit?

High Blood Pressure and Cardiovascular Prevention

Volumn 14, Issue 1, 2007, Pages 5-10

  Schiavoni, Marzia ^a,c   Cosentino, Francesco ^a   Camici, Giovanni G ^b   Luescher, Thomas F ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cardiovascular disease; Diabetes; Endothelial dysfunction; Mitochondria; Oxidative stress; p66shc

Indexed keywords

ADAPTOR PROTEIN; ADVANCED GLYCATION END PRODUCT; HEXOSAMINE; NITRIC OXIDE; PROTEIN KINASE C; PROTEIN P66SHC; UNCLASSIFIED DRUG;

ARTERY DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HEART FUNCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL;

EID: 33947720462     PISSN: 11209879     EISSN: None     Source Type: Journal    
DOI: 10.2165/00151642-200714010-00002     Document Type: Review

References (42)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14 Suppl. 5: S1-85
2. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-200
3. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81
4. Cosentino F, Luescher TF. Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol 1998; 32: 54-61
5. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Mol 1994; 16: 383-91
6. Creager MA, Luscher TF, Cosentino F, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003; 108: 1527-32
7. Luscher TF, Creager MA, Beckman JA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation 2003; 108: 1655-61
8. Brunner H, Cockcroft JR, Deanfield J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on endothelins and endothelial factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-46
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
11. Shivalkar B, Dhondt D, Goovaerts I, et al. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol 2006; 97: 77-82
12. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium- dependent vasodilatation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6
13. William SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilatation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-74
14. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12
15. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium dependent and independent vasodilatation in patients with type 2 diabetes mellitus. Diabetologia 1992; 35: 771-6
16. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-23
17. Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87: 1123-32
18. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 1999; 13: 23-30
19. Giardino I, Edelstein D, Brownlee M. Non enzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-7
20. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-66
21. Wells L, Hart GW. O-GlcNAc turns twenty: functional implication for posttranslational modification of nuclear and cytosolic protein with a sugar. FEBS Lett 2003; 546: 154-8
22. Korshunov SS, Skulachev VP, Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 1997; 416: 15-8
23. Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycaemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-57
24. Giorgio M, Migliaccio E, Orsini F, et al. Electron transfer between cytochrome C and p66shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell 2005; 122: 221-33
25. Cosentino F, Hishikawa K, Katusic ZS, et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-8
26. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human aortic endothelial cells. Circulation 2003; 107: 1017-23
27. Kouroedov A, Eto M, Joch H, et al. Selective inhibition of protein kinase Cβ2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 2004; 110: 91-6
28. Haller H, Baur E, Quass P, et al. High glucose concentration and protein kinase C isoforms in vascular smooth muscle cells. Kidney Int 1995; 47: 1057-67
29. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90
30. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-13
31. Francia P, delli Gatti C, Bachschmid M, et al. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004; 110: 2889-95
32. Anversa P, Kajstura J, Leri A, et al. Life and death of cardiac stem cells: a paradigm shift in cardiac biology. Circulation 2006; 113: 1451-63
33. Rota M, LeCapitaine N, Hosoda T, et al. Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66 shc gene. Circ Res 2006; 99: 42-52
34. Pacher P, Obrosova IG, Mabley JG, et al. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem 2005; 12: 267-75
35. Johansen JS, Harris AK, Rychly DJ, et al. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc Diabetol 2005; 4: 5
36. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycaemia attenuates endothelium-dependent vasodilatation in humans in vivo. Circulation 1998; 97: 1695-701
37. Beckman JA, Goldfine AB, Gordon MB, et al. Ascorbate restores endothelium-dependent vasodilatation impaired by acute hyperglycaemia in humans. Circulation 2001; 103: 1618-23
38. Haidara MA, Yassin HZ, Rateb M, et al. Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 2006; 4: 215-27
39. Yao EH, Yu Y, Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr Vasc Biotechnol 2006; 7: 101-8
40. Meier JJ, Bhushan A, Butler PC. The potential for stem cell therapy in diabetes. Pediatr Res 2006; 56: R65-73
41. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600
42. Wollert KC, Drexler H. Clinical application of stem cells for the heart. Circ Res 2005; 96: 151-63